Search results
Anixa advances CAR-T trial for ovarian cancer with fifth patient By Investing.com
Investing.com· 22 hours agoAnixa Biosciences, Inc. (NASDAQ: NASDAQ:ANIX), a clinical-stage biotechnology company, has begun...
...IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF...
FOX 5 San Diego· 6 days agoAmgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small ...
Is CRISPR Therapeutics a Millionaire Maker?
Motley Fool via Yahoo Finance· 2 hours agoSince the U.S. Food and Drug...Administration (FDA) granted approvals for both indications only in December 2023 and January 2024, respectively, the ...
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
FOX 23 News Albany· 1 day agoThe study is being conducted through a research partnership with Moffitt Cancer Center.
FOXO1 enhances CAR T cell fitness and function - Nature Biotechnology
Nature· 5 days agoCAR T cell therapies are limited by exhaustion of these cells in vivo, especially in treating solid tumors. Positive treatment responses have been associated ...
AstraZeneca to harness China's 'explosion' of innovation to boost cell therapy R&D
FierceBiotech· 1 day agoAstraZeneca’s growing presence in China will play a key role in the Big Pharma’s cell therapy...
Flexibility of alternative trial designs crucial for cell and gene therapy research
Clinical Trials Arena via Yahoo Finance· 2 days agoDespite it being difficult to randomise a gene therapy trial, in ophthalmology, sham controls are...
Henrietta Lacks’ Family Can Advance Ultragenyx Cell Use Suit
Bloomberg Law· 2 days agoThe family of Henrietta Lacks, a Black woman whose “immortal cell line” has led to medical innovations, such as the polio vaccine and gene mapping, can proceed with its lawsuit ...
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Motley Fool via Yahoo Finance· 4 hours agoAmtagvi is approved for advanced melanoma, the deadliest of skin cancers -- and this represents the...
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
The Motley Fool via AOL· 4 hours agoAmtagvi is approved for advanced melanoma, the deadliest of skin cancers -- and this represents the...
